Analyst Consensus ?
ConsensusBuy56 ratings
Bullish4885.7%
Neutral712.5%
Bearish11.8%
FN2 Earnings Intelligence
Vertex Pharmaceuticals Incorporated analyst ratings
Vertex Pharmaceuticals Incorporated (VRTX) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$515.44Current
$175Low
$474.33Average
$665High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 12, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Aug 5, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 5, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 4, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Aug 4, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Aug 4, 2026 |
| UBS | Buy | Buy | Maintain | Jul 13, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 7, 2026 |
| Baird | Underperform | Underperform | Maintain | Jul 7, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 5, 2026 |
| Bernstein | Outperform | Outperform | Maintain | May 5, 2026 |
| Maxim Group | Buy | Hold | Upgrade | Mar 18, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Mar 10, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Mar 10, 2026 |
| Citigroup | Buy | Buy | Maintain | Mar 10, 2026 |
| B of A Securities | Buy | Buy | Maintain | Mar 10, 2026 |
| HC Wainwright& Co. | Buy | Buy | Maintain | Feb 17, 2026 |
| Stifel | Hold | Hold | Maintain | Feb 13, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Feb 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jan 23, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jan 6, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Dec 29, 2025 |
| Wells Fargo | Overweight | Overweight | Maintain | Dec 10, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 8, 2025 |
| Guggenheim | Buy | Buy | Maintain | Aug 6, 2025 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 5, 2025 |
| Needham | Hold | Hold | Maintain | May 6, 2025 |
| Piper Sandler | Overweight | Overweight | Maintain | Jan 27, 2025 |
| Jefferies | Buy | Hold | Upgrade | Dec 9, 2024 |
| Argus Research | Buy | Buy | Maintain | Jun 17, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 31, 2024 |
| William Blair | Outperform | Outperform | Maintain | May 30, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Feb 8, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jun 13, 2022 |
| Raymond James | Perform | Market Perform | Maintain | Jul 1, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 2, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jun 24, 2020 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Apr 30, 2020 |
| CFRA | Buy | Buy | Maintain | Apr 30, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 31, 2020 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 6, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 20, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Oct 31, 2019 |
| H.C. Wainwright | Buy | Neutral | Upgrade | Oct 26, 2018 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Dec 13, 2017 |
| DA Davidson | Buy | Buy | Maintain | Sep 29, 2017 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jul 19, 2017 |
| Janney Capital | Buy | Neutral | Upgrade | Jul 19, 2017 |
| Leerink Swann | Outperform | Outperform | Maintain | Mar 8, 2016 |
| BTIG Research | Buy | Buy | Maintain | Jan 6, 2015 |
| Summer Street | Neutral | Buy | Downgrade | Oct 30, 2013 |
| Wunderlich | Buy | Buy | Maintain | May 17, 2013 |
| Lazard | Neutral | Buy | Downgrade | Jan 15, 2013 |
| Brean Capital | Buy | Hold | Upgrade | May 8, 2012 |
| ISI Group | Buy | Neutral | Upgrade | May 7, 2012 |
| Bank oferica | Buy | Buy | Maintain | Mar 14, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $515.44. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Terence Flynn | $665 | $547.65 | +29.0% | Sep 1, 2026 |
| Goldman Sachs | Analyst unavailable | $653 | $544.52 | +26.7% | Sep 1, 2026 |
| Bernstein | Jeffrey Walch | $608 | $530.29 | +18.0% | Aug 11, 2026 |
| Wolfe Research | Andy Chen | $562 | $522.78 | +9.0% | Aug 10, 2026 |
| Truist Financial | Analyst unavailable | $565 | $488.56 | +9.6% | Aug 5, 2026 |
| Barclays | Analyst unavailable | $617 | $478.7 | +19.7% | Aug 5, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $595 | $470.72 | +15.4% | Aug 4, 2026 |
| Canaccord Genuity | Analyst unavailable | $442 | $470.72 | -14.2% | Aug 4, 2026 |
| Stifel Nicolaus | Analyst unavailable | $500 | $470.72 | -3.0% | Aug 4, 2026 |
| UBS | Analyst unavailable | $585 | $481.7 | +13.5% | Jul 13, 2026 |
| Truist Financial | Analyst unavailable | $560 | $479.02 | +8.6% | Jul 13, 2026 |
| RBC Capital | Analyst unavailable | $570 | $529.59 | +10.6% | Jul 7, 2026 |
| Robert W. Baird | Analyst unavailable | $350 | $529.59 | -32.1% | Jul 7, 2026 |
| Truist Financial | Danielle Brill | $542 | $435.93 | +5.2% | May 27, 2026 |
| Barclays | Analyst unavailable | $615 | $424.36 | +19.3% | May 6, 2026 |
| Morgan Stanley | Analyst unavailable | $616 | $417.72 | +19.5% | May 5, 2026 |
| RBC Capital | Brian Abrahams | $543 | $429.85 | +5.3% | May 5, 2026 |
| Bernstein | Analyst unavailable | $572 | $429.85 | +11.0% | May 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $436 | $429.85 | -15.4% | May 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $437 | $423.24 | -15.2% | Apr 30, 2026 |
| Morgan Stanley | Analyst unavailable | $612 | $436.89 | +18.7% | Apr 10, 2026 |
| Truist Financial | Joon Lee | $525 | $499.14 | +1.9% | Mar 10, 2026 |
| Jefferies | Akash Tewari | $580 | $496.5 | +12.5% | Mar 10, 2026 |
| BMO Capital | Evan David Seigerman | $600 | $487.57 | +16.4% | Mar 2, 2026 |
| Canaccord Genuity | Analyst unavailable | $441 | $491.47 | -14.4% | Feb 17, 2026 |
| Barclays | Eliana Merle | $607 | $491.47 | +17.8% | Feb 17, 2026 |
| H.C. Wainwright | Andrew Fein | $591 | $491.47 | +14.7% | Feb 17, 2026 |
| Morgan Stanley | Terence Flynn | $570 | $497.42 | +10.6% | Feb 13, 2026 |
| Scotiabank | Louise Chen | $558 | $493.98 | +8.3% | Feb 13, 2026 |
| RBC Capital | Analyst unavailable | $541 | $496.02 | +5.0% | Feb 13, 2026 |
| Bernstein | Analyst unavailable | $577 | $497.21 | +11.9% | Feb 13, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $590 | $495.11 | +14.5% | Feb 13, 2026 |
| Stifel Nicolaus | Paul Matteis | $466 | $465.02 | -9.6% | Feb 13, 2026 |
| H.C. Wainwright | Andrew Fein | $518 | $465.02 | +0.5% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $606 | $474.17 | +17.6% | Jan 27, 2026 |
| UBS | Analyst unavailable | $545 | $474.09 | +5.7% | Jan 26, 2026 |
| Evercore ISI | Cory Kasimov | $530 | $469.11 | +2.8% | Jan 23, 2026 |
| RBC Capital | Brian Abrahams | $546 | $461.14 | +5.9% | Jan 22, 2026 |
| UBS | Michael Yee | $535 | $468.38 | +3.8% | Jan 6, 2026 |
| Leerink Partners | Analyst unavailable | $525 | $462.12 | +1.9% | Dec 29, 2025 |
| Morgan Stanley | Analyst unavailable | $564 | $461.48 | +9.4% | Dec 5, 2025 |
| Morgan Stanley | Terence Flynn | $516 | $433.15 | +0.1% | Dec 3, 2025 |
| RBC Capital | Analyst unavailable | $415 | $426.93 | -19.5% | Nov 4, 2025 |
| Cantor Fitzgerald | Carter Gould | $485 | $427.3 | -5.9% | Nov 4, 2025 |
| Stifel Nicolaus | Analyst unavailable | $445 | $426 | -13.7% | Nov 4, 2025 |
| Barclays | Gena Wang | $414 | $426 | -19.7% | Nov 4, 2025 |
| Morgan Stanley | Analyst unavailable | $438 | $413.93 | -15.0% | Oct 10, 2025 |
| Leerink Partners | Analyst unavailable | $456 | $381.87 | -11.5% | Sep 25, 2025 |
| Truist Financial | Analyst unavailable | $490 | $374.98 | -4.9% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $455 | $374.98 | -11.7% | Aug 5, 2025 |
| UBS | Eliana Merle | $553 | $374.98 | +7.3% | Aug 5, 2025 |
| BMO Capital | Analyst unavailable | $530 | $374.98 | +2.8% | Aug 5, 2025 |
| H.C. Wainwright | Analyst unavailable | $478 | $374.98 | -7.3% | Aug 5, 2025 |
| Morgan Stanley | Analyst unavailable | $439 | $374.98 | -14.8% | Aug 5, 2025 |
| RBC Capital | Brian Abrahams | $420 | $441.99 | -18.5% | Jun 17, 2025 |
| Scotiabank | Greg Harrison | $442 | $450.03 | -14.2% | May 6, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $535 | $490.47 | +3.8% | Apr 22, 2025 |
| BMO Capital | Evan Seigerman | $545 | $461.68 | +5.7% | Jan 31, 2025 |
| Wells Fargo | Mohit Bansal | $460 | $441.52 | -10.8% | Jan 30, 2025 |
| Morgan Stanley | Terence Flynn | $456 | $409.56 | -11.5% | Jan 10, 2025 |
| RBC Capital | Brian Abrahams | $400 | $469.22 | -22.4% | Dec 19, 2024 |
| Jefferies | Michael Yee | $550 | $462.1 | +6.7% | Dec 9, 2024 |
| Oppenheimer | Hartaj Singh | $540 | $499.1 | +4.8% | Nov 5, 2024 |
| RBC Capital | Brian Abrahams | $451 | $499.88 | -12.5% | Nov 5, 2024 |
| Canaccord Genuity | Whitney Ijem | $361 | $478.09 | -30.0% | Oct 22, 2024 |
| BMO Capital | Evan David Seigerman | $566 | $485.74 | +9.8% | Oct 21, 2024 |
| Goldman Sachs | Salveen Richter | $598 | $483 | +16.0% | Oct 21, 2024 |
| Bank of America Securities | Geoff Meacham | $541 | $482.12 | +5.0% | Oct 14, 2024 |
| RBC Capital | Brian Abrahams | $437 | $458.94 | -15.2% | Oct 9, 2024 |
| Truist Financial | Joon Lee | $550 | $494.46 | +6.7% | Aug 5, 2024 |
| Oppenheimer | Hartaj Singh | $550 | $477.86 | +6.7% | Aug 5, 2024 |
| Wolfe Research | Andy Chen | $576 | $476.91 | +11.7% | Aug 5, 2024 |
| H.C. Wainwright | Andrew Fein | $600 | $505.78 | +16.4% | Aug 2, 2024 |
| Argus Research | Jasper Hellweg | $550 | $474.61 | +6.7% | Jun 17, 2024 |
| RBC Capital | Brian Abrahams | $421 | $483.28 | -18.3% | Jun 11, 2024 |
| BMO Capital | Evan David Seigerman | $500 | $443.05 | -3.0% | May 31, 2024 |
| Raymond James | Christopher Raymond | $456 | $413.42 | -11.5% | May 7, 2024 |
| RBC Capital | Brian Abrahams | $424 | $402.5 | -17.7% | May 7, 2024 |
| H.C. Wainwright | Andrew Fein | $462 | $397.58 | -10.4% | Apr 11, 2024 |
| Evercore ISI | Liisa Bayko | $438 | $397.58 | -15.0% | Apr 11, 2024 |
| Morgan Stanley | Analyst unavailable | $285 | $297.18 | -44.7% | Feb 8, 2023 |
| H.C. Wainwright | Analyst unavailable | $326 | $308.54 | -36.8% | Feb 8, 2023 |
| Leerink Partners | Analyst unavailable | $365 | $308.54 | -29.2% | Feb 8, 2023 |
| Argus Research | Analyst unavailable | $340 | $310.86 | -34.0% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $253 | $290.68 | -50.9% | Aug 8, 2022 |
| H.C. Wainwright | Analyst unavailable | $300 | $279.54 | -41.8% | Aug 5, 2022 |
| Cantor Fitzgerald | Olivia Brayer | $365 | $290.01 | -29.2% | Jul 12, 2022 |
| Stifel Nicolaus | Paul Matteis | $240 | $295.46 | -53.4% | Jul 11, 2022 |
| Argus Research | Jasper Hellweg | $280 | $287.32 | -45.7% | Jul 2, 2022 |
| Cowen & Co. | Analyst unavailable | $310 | $248.96 | -39.9% | Jun 13, 2022 |
| Morgan Stanley | Matthew Harrison | $250 | $261.96 | -51.5% | May 3, 2022 |
| Piper Sandler | Analyst unavailable | $249 | $279.02 | -51.7% | Apr 22, 2022 |
| Oppenheimer | Hartaj Singh | $350 | $272.39 | -32.1% | Apr 6, 2022 |
| Robert W. Baird | Brian Skorney | $240 | $251.88 | -53.4% | Mar 22, 2022 |
| BMO Capital | Evan Seigerman | $274 | $251.88 | -46.8% | Mar 22, 2022 |
| Jefferies | Michael Yee | $275 | $228.22 | -46.6% | Jan 27, 2022 |
| Wolfe Research | Andrew Galler | $282 | $228.22 | -45.3% | Jan 27, 2022 |
| J.P. Morgan | Cory Kasimov | $288 | $228.22 | -44.1% | Jan 27, 2022 |
| Morgan Stanley | Matthew Harrison | $208 | $228.22 | -59.6% | Jan 27, 2022 |
| Cowen & Co. | Phil Nadeau | $300 | $229.68 | -41.8% | Jan 24, 2022 |
| Leerink Partners | Geoff Porges | $175 | $204.45 | -66.0% | Dec 2, 2021 |
| Guggenheim | Debjit Chattopadhyay | $286 | $205 | -44.5% | Dec 1, 2021 |
| Bank of America Securities | Geoff Meacham | $275 | $181.4 | -46.6% | Nov 2, 2021 |
| Cantor Fitzgerald | Alethia Young | $281 | $193.02 | -45.5% | Jun 11, 2021 |
| Barclays | Gena Wang | $285 | $193.02 | -44.7% | Jun 11, 2021 |
| UBS | Colin Bristow | $279 | $212.68 | -45.9% | May 12, 2021 |
Track every rating change on VRTX the moment it posts. Free to start.
Start free